Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study

• by Yen-Ju Chen, Wei-Li Ho, Hsian-Min Chen, Yi-Ming Chen, Hsin-Hua Chen

• June 22, 2026

Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides

• by Sheng-Guang Li, Yadan Zou, Ji Li, Lina Zhang, Jing Zhang, Ting Long, Ruohan Yu, Yanfeng Zhang

• June 4, 2026

Lipid changes after interleukin-6 blockade in rheumatoid arthritis: beyond cholesterol elevation toward hepatic inflammatory-lipoprotein remodeling

• by Na Yuan, Zipei Zhang, Xiancheng Wang, Ting Li

• June 23, 2026

Hair Repigmentation Reported With Baricitinib in Canities Subita

A single case suggests a possible benefit, but confounding factors and the off-label setting temper the conclusions.

• by Andrea Surnit

• June 15, 2026

• 4 min